References
- Kemeny N, Golbey R. A chemotherapeutic approach to colorectal carcinoma. Neoplasms of Colon, Rectum and Anus, M W Stearns, Jr. Wiley, New York 1980; 155–168
- Kessel D, Hall T C. Studies on drug transport by normal human leukocytes. Biochem Pharmacol 1967; 16: 2395–2403
- Danenberg P V, Danenberg K D. Effect of 5,10-methylenetetra-hydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthase: Evidence for an ordered mechanism. Biochemistry 1978; 17: 4018–4024
- Moran R G, Keyomars K. Biochemical rationale for the synergism of 5-fluorouracil and folinic acid. NCI Monogr 1987; 5: 159–163
- Erlichman C, Fine S, Wong A, et al. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinomas. J Clin Oncol 1988; 6: 469–475
- Doroshal J H, Multhauf P, Leong L, et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 1990; 8: 491–501
- Poon M A, O'Connell M J, Moertel C F, et al. Biochemical modulations of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407–1418
- Machover D, Goldschmidt E, Chollet P, et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. NCI Monogr 1987; 5: 193–198
- Bruchner H W, Petrelli N J, Stabein D, et al. Comparison of unique leucovorin and 5-fluorouracil “escalating” and “maximum“ dosage strategies. NCI Monogr 1987; 5: 179–184
- Stein T A, Burns G P, Bailey B, et al. Measurement of 5-fluorouracil and its active metabolites in tissue. J Chromotogr 1990; 507: 259–265
- Berger S H, Hakala M T. Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. Mol Pharmacol 1984; 25: 303–309
- Rustum Y M, Trave F, Zakrzewski S F, et al. Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monogr 1987; 5: 165–170
- Grem J L, McAtee N, Murphy R F, et al. A pilot study of interferon alpha-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol 1991; 9: 1811–1820
- MacMillan W E, Wolberg W H, Welling P G. Pharmacokinetics of 5-fluorouracil in humans. Cancer Res 1978; 38: 3479–3482
- Finan P J, Chisholm W M, Woodhouse L, et al. The relationship between plasma pharmacokinetics and tissue metabolites of 5-fluorouracil (5-FU) in patients with colorectal cancer. Eur J Surg Oncol 1987; 13: 349–353
- Milano G, Roman P, Khater R, et al. Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int J Cancer 1988; 41: 537–541
- Minsky B D, Cohen A M, Kemeny N, et al. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol 1992; 10: 79–84
- Doroshow J H, Leong L, Margolin K, et al. Refractory metastatic breast cancer: Salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. J Clin Oncol 1989; 7: 439–444
- Swain S M, Lippman M E, Egan E F, et al. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 890–899